Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reiterated a Buy rating on Artiva Biotherapeutics (NASDAQ:ARTV) and maintained a price target of $23.
August 30, 2024 | 3:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Gil Blum has reiterated a Buy rating on Artiva Biotherapeutics and maintained a $23 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $23 price target by a reputable analyst suggests a positive outlook for Artiva Biotherapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100